BD intros 6-mm pen needle for injection pens
FRANKLIN LAKES, N.J. — BD is bringing a new option for patients using pen injection devices. The BD Ultra-Fine micro pen needle 6 mm x 32 gauge is set for distribution in September, bringing a new needle length option to patients with diabetes who inject insulin.
The BD Ultra-Fine line also includes the 4 mm x 32 gauge, 5 mm x 31 gauge, 8 mm x 31 gauge and 12.7 mm x 29 gauge needles. The company said that the new needles were compatible with leading pen injection devices. With shorter needles in their pen injectors, patients with diabetes are less likely to accidentally inject their daily dose of insulin into a muscle, BD said.
“We added the BD Ultra-Fine micro pen needles to ensure BD has a comprehensive portfolio that provide options to patients and reinforces BD's commitment to providing the best solutions possible for people with specific preferences while managing their diabetes and striving for the best clinical outcomes," BD worldwide president of diabetes care and digital health Nabil Shabshab said. "This new needle will help ensure that people with diabetes who prefer a 6mm pen needle will be able to experience the quality and performance of BD Ultra-Fine pen needles.”
Mandatory controlled substance e-prescribing bill winds its way through Congress
A recently introduced bill from Reps. Katherine Clark, D-Mass., and Markwayne Mullin, R-Okla., has garnered interest from longtime proponents of e-prescribing in the retail pharmacy industry. The Every Prescription Conveyed Securely Act would require all controlled substances to be electronically prescribed.
The National Association of Chain Drug Stores was quick to praise the legislation. “[This] is an important step in combatting the abuse and diversion of prescription opioid medications,” NACDS president and CEO Steve Anderson wrote to the bill’s co-sponsors. “Electronic prescribing of controlled substances adds new dimensions of safety and security.”
In addition to its advocacy for e-prescribing, NACDS previously partnered with the National Community Pharmacy Association, helped create the health information network that merged with RxHub and now operates as Surescripts. In 2016, Surescripts said that it saw increased adoption of controlled substance e-prescribing, delivering 45.3 million scripts for controlled substances in 2016 — a 256% increase over the previous year.
FDA approves Perrigo’s Exalgo extended-release generic
SILVER SPRING, Md. — Perrigo is adding to its portfolio of opioid generics. The Food and Drug Administration has approved the company’s generic of Exalgo (hydromorphone HCL, 32 mg) extended-release tablets.
The drug is an opioid indicated to manage moderate to severe pain in patients requiring continuous around-the-clock pain opioid analgesia for an extended period of time. Perrigo said it planned to make the generic available by the end of September.
The drug had brand and generic sales of $35 million for the 12 months ended July 2017, the company said.